

PHAXIAM



Building a Global Leader in AMR Infections Therapies

March 2024

- This document has been prepared by PHAXIAM (the “Company”) and is provided for information purposes only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris and Nasdaq. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness.
- This presentation does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of the Company in any jurisdiction.
- The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.
- The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accepts no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.
- This document contains information on the Company’s markets. This information has been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information.
- This document contains certain forward-looking statements. These statements are not guarantees of the Company’s future performance. These forward-looking statements relate to the Company’s future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company’s future performance and the Company’s actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company’s future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.
- Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables may not necessarily equal the sum of the individually rounded figures, amounts or percentages.
- All persons accessing this document must agree to the restrictions and limitations set out above.

Key Messages


Concern is growing about **AMR Infections**, the “New Global Pandemics”
Phage Therapy is the Therapeutic Solution for Multi-resistant Bacterial Infections

- A new momentum for Phagotherapy with **an increased interest from financial investors**
- Ambitious strategy by focusing on High-Value Indications targeting **Life-Saving Therapeutics** according to Pharma standards
- De-risked **Clinical Strategy** with **real-life demonstrated Clinical Efficacy and Safety**
- **Performing Sales, First-to-Market** anticipating Market access in 2027 (Early Access Pathway)
- Secured and in place **GMP-Manufacturing** (Pharma standards) & **Logistics Capabilities**
- **Environmental-friendly technology**
- Robust execution Capabilities

Agenda


1. Global Context
2. PHAXIAM Differentiation
3. Development Strategy
4. Capabilities
5. Communications & Financing

The Antimicrobial Resistance (AMR)




There is a CRITICAL NEED to address Antimicrobial Resistance

Phage Therapy, a Solution for Resistant Infections



Bacteriophages:
viruses, natural
predators of
bacteria




Unique mode of action

- ◆ **Specificity**
- ◆ **Speed**
(less than 45 min)
- ◆ **Self-replication** down to the last bacterium


Phage Therapy allows **SIMPLE, EFFECTIVE** and **WELL-TOLERATED** treatments

The Strong Momentum of Phage Therapy



Phage Therapy is a TOP-10 INNOVATION to be developed according to the 2023 World Economic Forum

Competitive Landscape



PHAXIAM is the EUROPEAN LEADER in Phage Technology
Direct major Competitors are US-based
Very Recent Merger between BiomX & APT

Reinforced interest in Phage Therapy

Major Commitment from Top Tier US investors in March 2024




Purchase agreement with a \$50M private placement financing led by Top tier investor base, incl. Deerfield and Orbimed



Armata Pharmaceuticals has recently announced \$35M refinancing with Innoviva

Key Technology Assets for PHAXIAM Treatments



- 1 SELECT** phages to maximize breadth of repertoire
Internal PHAXIAM Technology and Expertise
- 2 PRODUCE** large scale GMP batches of high purity
Internal PHAXIAM process development Capabilities and Expertise
Industrial partnership to produce “off-the-shelf” GMP-grade phages
- 3 TEST PHAGOGRAM** for a precision therapy
PHAXIAM proprietary IVD Test
- 4 DISTRIBUTE** personalized therapeutics to patients' bed
Supply chain in place with a few days leadtime



Discovery, Screening, Characterization, GMP production, Testing, Distributing

Robust Real-life Clinical Data From ~100 Treated Patients

- STRONG SUPPORT from Regulatory Authorities & over 15 hospitals
- SEVERAL ROUTES OF ADMINISTRATION TESTED, including local, intravenous, nebulisation, ...
- 7 DIFFERENT INDICATIONS TREATED with a majority of PJI



PROMISING CLINICAL ACTIVITY RESULTS
(First 77 patients evaluated)
2018-2023

- EXCELLENT RESULTS observed in reported cases: safety + clinical benefit
- Several PUBLICATIONS

~80% CONTROL RATE of infection at 3months for PJI Patients (n=42)
VERY PROMISING Data in « hard to treat » population
(very severe infections - 2nd/3rd line antibiotics)

AAC* Regulatory Status from French Authority (June 2022)



COMPASSIONATE
ACCESS
AUTHORIZATION
(AAC)

SOURCE OF REVENUES

To be extended to OTHER AAC* INDICATIONS
Process towards an EARLY ACCESS AUTHORIZATION
To be extended to ORPHAN STATUS

An Important First Step for MARKET ACCESS in EUROPE

Corporate Strategy

**POSITION THE COMPANY
AS A GLOBAL LEADER**

**EXPAND
CLINICAL PORTFOLIO IN
HIGH-VALUE INDICATIONS**

**INTENSIFY
BD ACTIVITIES
& ANTICIPATE MARKET
ACCESS**

**IMPLEMENT
GLOBAL
MANUFACTURING**

**BOOST
R&D CAPABILITIES
& EXPAND PHAGE
PLATFORM**



PHAXIAM

An Ambitious Clinical Development Strategy

Target High-Value Indications

Severe Resistant Infections with High unmet medical needs
high mortality rate / high budget impacts → claim high pricing

Accelerate the Path to Global Registration

Launch the 1st global randomized Phase 2 study at international scale
Leverage on potential Early access pathway (after phase 2 part)

Diversify Portfolio

Target several Life-Threatening Infections (Endocarditis, VAP*, ...)
Target several Virulent & Resistant Bacteria


*Ventilation-acquired Pneumopathies

Targeting High-value Resistant Infections

Life-Threatening Conditions

Potential Orphan Status Indications

The most severe Hospital-Acquired and Resistant Infections



A Balanced Clinical Portfolio



Leading Phage Therapy Platform

Leading Edge in Clinical Development

Regular Interactions with Regulatory Agencies & HTA agencies

Strong internal R&D, CMC & GMP Capabilities

Proprietary PHAGOGRAM® IVD Solution

Large Phage Bank for the most critical bacterial Infections

Strong IP with 87 patents filed



Manufacturing & Logistics strategic capabilities

In-house process development & analytical science

In-house highly purified phages manufacturing


Strategic partnership with MB Pharma (CMO, EU) to manufacture GMP bacteriophages clinical batches

Pharmaceutical supply chain mastered to ensure robust and short lead time clinical supply (clinical studies, AAC,)

Major achievements



- > 35 GMP clinical batches produced
- Low Manufacturing COGS
- Available capacity till early market launch
- Short supply lead time (> 1 week)



Manufacturing & Logistics Capacities Fit to Address future Clinical Demand

Experienced & Complementary Leadership Team

Thibaut du Fayet
CEO



Eric Soyer
COO CFO



Pascal Birman, MD
CMO



Céline Bréda
CTO



Cindy Fevre
CSO



Jérôme Bailly
CQO



Karine Charton
CBO



Frédérique Vieville
CRO



Anne-Cécile Fumey
VP HR



Pherecydes and Erytech
merged to build
PHAXiAM
Leveraging on
Complementary Capabilities
from both Executive Teams

Expected Major Clinical Catalysts

CLINICAL
&
REGULATORY



Financial Position

Cash position as of December, 2023: €10.5m

Cash Runway into September 2024

Reviewing options to further extend cash Runway



Thanks | PHAXiAM